Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Glaucoma: Overview01:25

Glaucoma: Overview

1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Nicotinamide Supplementation and Primary Open-Angle Glaucoma in Patients With Ocular Hypertension.

JAMA ophthalmology·2026
Same author

Risk and Predictors of Fellow-Eye Involvement Following Unilateral Retinal Artery Occlusion.

Ophthalmology. Retina·2026
Same author

Comparative Five-Year Risks of Systemic Complications with Biologic versus Conventional Therapy in Non-infectious Uveitis.

Ophthalmology·2026
Same author

Systemic Statin Use and Reduced Risk of Repeat Retinal Detachment Repair: A Retrospective Cohort Study.

Ophthalmology. Retina·2026
Same author

Systemic Anemia and the Risk of Diabetic Macular Edema and Anti-VEGF Injections.

Ophthalmology. Retina·2026
Same author

Statin Intensity and the Risk of Noninfectious Uveitis.

Ophthalmology. Retina·2026

Related Experiment Video

Updated: Mar 27, 2026

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
09:28

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

9.5K

Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction.

Darius D Bordbar1, Ali O Mukhtar2,3, Asad Loya4

  • 1Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston.

JAMA Ophthalmology
|March 26, 2026
PubMed
Summary
This summary is machine-generated.

Continuing intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy around cardiovascular events (CVE) like stroke or myocardial infarction (MI) was not linked to increased mortality or major functional deficits. This supports the safety of uninterrupted anti-VEGF treatment during the peri-CVE period.

More Related Videos

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.9K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K

Related Experiment Videos

Last Updated: Mar 27, 2026

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
09:28

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

9.5K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.9K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K

Area of Science:

  • Ophthalmology
  • Cardiology
  • Pharmacology

Background:

  • Limited evidence exists on the systemic safety of continuing intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in patients experiencing stroke or myocardial infarction (MI).
  • Decisions regarding pausing or modifying anti-VEGF treatment post-cardiovascular event (CVE) are challenging due to this lack of data.

Purpose of the Study:

  • To evaluate associations between peri-cardiovascular event (peri-CVE) anti-VEGF treatments and mortality or major functional outcomes in patients with CVE.
  • To determine if systemic outcomes differ based on the specific anti-VEGF agents used.

Main Methods:

  • Retrospective cohort study utilizing deidentified electronic health records (EHR) from the TriNetX network (2005-2025).
  • Propensity score matching (PSM) was used to balance demographics, comorbidities, and treatments between patients receiving peri-CVE anti-VEGF and controls.
  • Primary outcomes included 3-month and 1-year all-cause mortality, poststroke neurologic deficits, and post-MI heart failure.

Main Results:

  • Peri-CVE anti-VEGF was associated with significantly lower 3-month and 1-year mortality following stroke and MI.
  • Fewer neurologic deficits were observed at 3 months post-stroke, but not at 1 year.
  • Lower rates of heart failure at 3 months post-MI were noted, but not at 1 year.
  • No significant differences in outcomes were found among aflibercept, bevacizumab, or ranibizumab.

Conclusions:

  • Continuing intravitreal anti-VEGF therapy during the peri-CVE period is not associated with increased mortality or morbidity.
  • The choice of anti-VEGF agent (aflibercept, bevacizumab, ranibizumab) did not impact outcomes.
  • Findings support the safety of maintaining current anti-VEGF treatment regimens without modification in patients experiencing stroke or MI.